Efficacy
This presentation is the property of its rightful owner.
Sponsored Links
1 / 21

Efficacy PowerPoint PPT Presentation


  • 105 Views
  • Uploaded on
  • Presentation posted in: General

Efficacy. Paul Meyers, MD Vice-Chairman, Dept of Pediatrics Memorial Sloan-Kettering Cancer Center. 2023.01. Osteosarcoma Survival: SEER Data. 1993-2002. 2503.01. 1.0. 0.8. 12. 12. MTP Cohort 1 (12wk). 21. 20. Historical control. 16. 11. MTP Cohort 2 (24wk). 0.6.

Download Presentation

Efficacy

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Efficacy

Efficacy

Paul Meyers, MD

Vice-Chairman, Dept of PediatricsMemorial Sloan-Kettering Cancer Center

2023.01


Osteosarcoma survival seer data

Osteosarcoma Survival:SEER Data

1993-2002

2503.01


Phase 2 results in relapsed osteosarcoma with lung metastases

1.0

0.8

12

12

MTP Cohort 1 (12wk)

21

20

Historical control

16

11

MTP Cohort 2 (24wk)

0.6

Disease-Free Survival

0.4

0.2

0

0

2

4

6

8

10

12

Phase 2 Results in Relapsed Osteosarcoma with Lung Metastases

Total

Fail

Years

Kleinerman ES et al, Am.J. Clin. Onc. 18:93, 1995

2025.04


Landmark phase 3 trial

Landmark Phase 3 Trial

  • NCI-sponsored, Cooperative Group study

    • Designed and conducted independently of corporate sponsor

  • Largest study completed in osteosarcoma

    • 178 sites – 1/3 of eligible incident cases in US

  • Newly diagnosed (within 30 days; age <31)

    • 678 non-metastatic resectable disease

    • 115 with more advanced disease

2027.01


Phase 3 study design

A+

Cisplatin, Doxorubicin, HDMTX, MTP

Cisplatin, Ifosfamide,Doxorubicin, HDMTX, MTP

B+

Phase 3 Study Design

INDUCTION

DEFINITIVESURGERY

MAINTENANCE

A

Cisplatin

Doxorubicin

HDMTX

A-

Cisplatin, Doxorubicin, HDMTX

Cisplatin, Ifosfamide, Doxorubicin, HDMTX

B

Ifosfamide

Doxorubicin

HDMTX

B-

20

27

36

Weeks

2028.03


Phase 3 study endpoints

Phase 3 Study Endpoints

  • DFS

    • Putative surrogate for OS

    • Prospectively defined primary endpoint

    • “To determine whether MTP can improve DFS…”

    • “To compare the results of a prospective, randomized trial of two chemotherapeutic regimens…” (A vs. B)

  • Survival

    • “To improve the survival of patients with osteogenic sarcoma”

2034.02


Data sources

COG

Patient Records

CRFs

Database

1

2

Patient Records

Clinical Sites

3

2003

3

Patient Records

IDM

Data Sources

2403.03


Baseline demographics and disease characteristics

Baseline Demographics and Disease Characteristics

2120.03


Primary analysis dfs

Primary Analysis: DFS

2003 ITT

2134.01


Primary analysis dfs kaplan meier

Disease-Free Survival

2003 ITT

100%

80%

MTP

60%

No MTP

40%

N

Events

20%

MTP

338

102

no MTP

340

126

0%

0

2

4

6

8

10

12

Years

Primary Analysis: DFS (Kaplan-Meier)

2041.03


Primary analysis survival

Primary Analysis: Survival

2003 ITT

2135.01


Primary analysis survival kaplan meier

Overall Survival

2003 ITT

100%

MTP

80%

60%

No MTP

40%

N

Events

20%

MTP

338

63

no MTP

340

85

0%

0

2

4

6

8

10

12

Years

Primary Analysis: Survival (Kaplan-Meier)

2038.04


Data sources1

COG

Patient Records

CRF

Database

1

2

Patient Records

Clinical Sites

3

Patient Records

IDM

Data Sources

2006

2455.01


Follow up 2003 and 2006

Follow Up 2003 and 2006

2003 ITT

2006 ITT

no MTP

MTP

MTP

no MTP

Time to Last Contact

Time to Last Contact

2229.05


Confirmatory analysis 2006 survival

Confirmatory Analysis 2006: Survival

2006 ITT

2545.01


Confirmatory 2006 analysis survival kaplan meier

0

2

4

6

8

10

12

Years

Confirmatory 2006 Analysis: Survival (Kaplan-Meier)

Overall Survival

2006 Data

100%

MTP

80%

No MTP

60%

40%

N

Events

20%

MTP

338

73

no MTP

340

100

0%

2223.03


Safety

Safety

2457.01


Grade 3 or 4 adverse events reported by 3 of patients phase 3 itt

Grade 3 or 4 Adverse Events Reported by ≥3% of Patients: Phase 3 ITT

2428.01


Patient discontinuation maintenance

Patient Discontinuation (Maintenance)

2122.02


Osteosarcoma overall survival seer ages 0 29

1993-2002

1987-1992

1981-1986

1975-1980

Osteosarcoma: Overall Survival(SEER Ages 0 - 29)

2094.04


Osteosarcoma overall survival seer and cog 2006 data all patients

MTP

No MTP

SEER 1987-1992

SEER 1993-2002

SEER 1981-1986

SEER 1975-1980

Osteosarcoma: Overall SurvivalSEER and COG 2006 Data (All Patients)

2504.01


  • Login